Immunome (IMNM) and Zentalis (ZNTL), announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate, or ADC, with potential on track for IND submission in Q1 2025, and Zentalis’ proprietary ADC platform technology. Under the terms of the deal, Zentalis will receive an up-front payment of $35M in cash and Immunome common stock. Zentalis will be eligible to receive up to $275M of milestone payments for ZPC-21 and the platform technology in addition to mid-to-high single-digit royalties.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMNM:
- Immunome appoints Phil Roberts as Chief Technical Officer
- Biotech Alert: Searches spiking for these stocks today
- Immunome to acquire antibody-related assets, materials from Atreca
- Atreca announces asset purchase agreement for sale of assets to Immunome
- Immunome initiated with an Outperform at Wedbush
